

1Fu 1615

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Giblin et al.

Docket No.

P33027USW

Serial No.

10/508,761

Filing Date


September 22, 2004

Examiner

Group Art Unit

1615

Invention: (2-(1,4-Alkoxy)-Phenyl)-Cyclopent-1-Enyl) Aromatic Carbo and Heterocyclic Acid and Derivatives



I hereby certify that this Supplemental IDS w/accompanying papers

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

4-21-05

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)



14w

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Giblin et al.

Intl. Serial No.: 10/508,761 Group Art Unit: 1615

Intl. File Date: September 22, 2004 Examiner: To Be Assigned

For: (2-((2-Alkoxy)-Phenyl)-Cyclopent-1-Enyl) Aromatic Carbo and Heterocyclic Acid and Derivatives

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed: 13-60
 Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,




Lorie Ann Morgan
Registration No. 38,181

Date: *21 Apr 2005*

GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988


**FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT**

SERIAL NO.	10/508,761
FILING DATE	September 22, 2004
APPLICANT	Giblin et al.
GROUP	1615
EXAMINER	
ATTORNEY DOCKET NO.	P33027USW

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
1	6,495,149	Dec. 17, 2002	Scavone et al.			
2	6,440,963	Aug. 27, 2002	Leonardi et al.			
3	US 2002 045605	Apr. 18, 2002	Kargman et al.			
4	6,136,839	Oct. 24, 2000	Isakson et al.			
5	5,972,986	Oct. 26, 1999	Seibert et al.			
6	5,840,746	Nov. 24, 1998	Ducharme et al.			
7	5,663,180	Sept. 2, 1997	Reitz et al.			
8	5,474,995	Dec. 12, 1995	Ducharme et al.			
9	5,344,991	Sept. 6, 1994	Reitz et al.			
10	5,420,287	May 30, 1995	Reitz, et al.			

Continue on page 2
FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
13	EP 1264847	Dec. 11, 2002	EUROPE			Abstract only
14	JP 2002363748	Dec. 18, 2002	JAPAN			Abstract only
15	WO 02/099435	Dec. 12, 2002	WIPO			
16	EP 1251126	Oct. 23, 2002	EUROPE			
17	WO 01/081332	Nov. 1, 2001	WIPO			
18	WO 00/53149	Sept. 14, 2000	WIPO			
19	WO 00/47553	Aug. 17, 2000	WIPO			
20	WO 99/58487	Nov. 19, 1999	WIPO			
21	WO 99/17776	Apr. 15, 1999	WIPO			
22	WO 98/55468	Dec. 10, 1998	WIPO			
23	WO 98/16227	Apr. 23, 1998	WIPO			
24	WO 97/16435	May 9, 1997	WIPO			
25	WO 97/11701	Apr. 3, 1997	WIPO			
26	WO 97/03667	Feb. 6, 1997	WIPO			
27	WO 96/41645	Dec. 27, 1996	WIPO			
28	WO 96/36623	Nov. 21, 1996	WIPO			
29	WO 96/11676	Apr. 25, 1996	WIPO			
30	WO 95/00501	Jan. 5, 1995	WIPO			
31	WO 95/17393	June 29, 1995	WIPO			
32	WO 95/05372	Feb. 23, 1995	WIPO			

Continue on page 2
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

58	Whitesell, J.K., et al. "Synthesis and Resolution of a New Chiral C2-Symmetric Bisphenol: Trans-1,2-Bis(2-Hydroxyphenyl)cyclopentane." <i>Tetrahedron Letters</i> , 1997, 38(15), pgs. 2589-2592.
59	Rathore, R., et al. "Efficient Hydrogenation of Sterically Hindered Olefins with Borane-Methyl Sulfide Complex." <i>Journal of Organic Chemistry</i> , 1996, 61(16), pgs. 5246-5256.
60	Malik, O.P., et al. "Studies on Cannabinoids: Part III. Synthesis of 9,10,11,11a-Tetrahydro-6H,8H-Pyrido(1,2-c) [1,3]benzoxazine." <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> , 1976, 14B(12), pgs 975-978.

Continue on page 2

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/508,761
	FILING DATE	September 22, 2004
	APPLICANT	Giblin et al.
	GROUP	1615
	EXAMINER	
	ATTORNEY DOCKET NO.	P33027USW

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	11	5,512681	Apr. 30, 1996	Boswell et al.			
	12	5,424,450	June 13, 1995	Boswell et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
33	GB 2,272,899		June 1, 1994	GREAT BRITAIN			
34	JP 06065213		March 8, 1994	JAPAN			Abstract only
35	JP 05224442		Sept. 3, 1993	JAPAN			Abstract only
36	EP 540009		May 5, 1993	EUROPE			
37	JP 04076087		March 10, 1992	JAPAN			Abstract only
38	DE 4034728		May 7, 1992	GERMANY			Abstract only
39	DE 4032522		Apr. 16, 1992	GERMANY			Abstract only
40	WO 97/38986		Oct. 23, 1997	WIPO			
41	WO 95/11883		May 4, 1995	WIPO			
42	WO 96/37496		Nov. 28, 1996	WIPO			
43	WO 94/05658		Mar. 17, 1994	WIPO			
44	JP 04235933		Aug. 25, 1992	JAPAN			Abstract only
45	EP 131302		Jan. 16, 1985	EUROPE			
46	AU 8311483		Mar. 3, 1982	AUSTRALIA			Abstract only
47	EP 52300		Nov. 13, 1980	EUROPE			Abstract only
48	DT 2405171		Feb. 19, 1973	GERMANY			Abstract only
49	NE 6610022		Aug. 2, 1965	NIGER			Abstract only
50	BEL 611179		Dec. 6, 1960	BELGIUM			X
51	DE 20211496		Nov. 19, 2002	GERMANY			Abstract only
52	WO 98/25896		June 18, 1998	WIPO			
53	EP 0799823		Oct. 8, 1997	EUROPE			
54	WO 01/19814		Mar. 22, 2001	WIPO			
55	WO 93/04045		Mar. 4, 1993	WIPO			
56	WO 93/04046		Mar. 4, 1993	WIPO			
57	WO 00/59506		Oct. 12, 2000	WIPO			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	